Thanks Tarecq for the AGM summary. Makes sense to focus on NASH given the size of market and lack of alternatives available. I'm looking forward to results released in the next 3-6months.
The only minor disappointment for me from the investor pack released today was the status of the anti infective portfolio. The animal studies on clostridium difficile are very compelling. It would be nice to progress this a bit faster.
Also, I'm looking forward to results released from the US army and navy. Was there much discussion at the AGM on the anti infective portfolio?
NASDAQ Public Offer, page-26
Add IMC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.002(2.04%) |
Mkt cap ! $22.79M | |||
| Open | High | Low | Value | Volume |
| 9.7¢ | 10.0¢ | 9.7¢ | $10.25K | 103.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 104328 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 33250 | 2 |
View Market Depth
| Last trade - 15.52pm 09/08/2024 (20 minute delay) ? |
| IMC (ASX) Chart |